General Hospital Psychiatry
Volume 27, Issue 4 , Pages 229-236 , July 2005

Nine-month predictors and outcomes of SSRI antidepressant continuation in primary care

  • James E. Aikens, Ph.D.

      Affiliations

    • Department of Family Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    • Department of Psychiatry, University of Michigan, Ann Arbor, MI 48109, USA
    • Corresponding Author InformationCorresponding author. Department of Family Medicine, University of Michigan, Box 0708, Ann Arbor, MI 48109, USA. Tel.: +1 734 998 7120x320; fax: +1 734 998 7335.
    • ,
  • Kurt Kroenke, M.D.

      Affiliations

    • Department of Medicine, Division of General Internal Medicine and Geriatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    • Regenstrief Institute, Indianapolis, IN 46202, USA
    • ,
  • Ralph W. Swindle, Ph.D.

      Affiliations

    • US Outcomes Research, U.S. Medical Division, Eli Lilly and Company, Indianapolis, IN 46285, USA
    • Department of Psychology, Indiana University-Bloomington, Bloomington, IN 47405, USA
    • ,
  • George J. Eckert, M.A.S.

      Affiliations

    • Department of Medicine, Division of Biostatistics, Indiana University School of Medicine, Indianapolis, IN 46202, USA

Received 26 January 2005 ,Revised 31 March 2005 ,Accepted 4 April 2005.

References 

  1. Depression Guideline Panel. Depression in primary care: volume 1. Detection and diagnosis. Clinical practice guideline, number 5. Rockville, (MD): US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, AHCPR Publication No. 93-0550, April 1993.
  2. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry. 2003;64:1465–1475
  3. Regier DA, Hirschfeld RM, Goodwin FK, Burke JD, Lazar JB, Judd LL. The NIMH depression awareness, recognition and treatment program: structure, aims, and scientific basis. Am J Psychiatry. 1998;145:1351–1357
  4. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;23:3095–3105
  5. Arean PA, Alvidrez J. Treating depressive disorders: who responds, who does not respond, and who do we need to study?. J Fam Pract. 2001;50:E2
  6. Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines. Impact on depression in primary care. JAMA. 1995;273:1026–1031
  7. Simon GE, Lin EH, Katon W, et al. Outcomes of “inadequate” antidepressant treatment. J Gen Intern Med. 1995;10:663–670
  8. Moride Y, Du Fort GG, Monette J, et al. Suboptimal duration of antidepressant treatments in the older ambulatory population of Quebec: association with selected physician characteristics. J Am Geriatr Soc. 2002;50:1365–1371
  9. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55:1128–1132
  10. Peveler R, Grorge C, Kinmonth A, Campbell M, Thompson C. Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomized controlled trial. BMJ. 1999;319:612–615
  11. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33:67–74
  12. Maddox JC, Levi M, Thompson C. The compliance with antidepressants in general practice. J Psychopharmacol. 1994;8:48–53
  13. Demyttenaere K, Enzlin P, Dewe W, Boulanger B, De Bie J, De Troyer W, et al. Compliance with antidepressants in a primary care setting: 1. Beyond lack of efficacy and adverse events. J Clin Psychiatry. 2001;62(Suppl. 22):30–33
  14. Thompson C, Peveler RC, Stephenson D, McKendrick J. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant. Am J Psychiatry. 2000;157(3):338–343
  15. Bull SA, Hunkeler EM, Lee JY, et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002;36:578–584
  16. Aikens JE, Nease DE, Nau DP, Klinkman MS, Schwenk TL. Perceived medication need, medication concerns, and adherence to maintenance-phase antidepressant therapy. Ann Fam Med. 2005;(3):23–30
  17. Demyttenaere K. Risk factors and predictors of compliance in depression. Eur Neuropsychopharmacol. 2003;13(Suppl 3):S69–S75
  18. Kobak KA, Taylor L, Katzelnick DJ, et al. Antidepressant medication management and Health Plan Employer Data Information Set (HEDIS) criteria: reasons for nonadherence. J Clin Psychiatry. 2002;63:727–732
  19. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;2:2947–2955
  20. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197–203
  21. Spitzer RL, Williams JBW, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 study. JAMA. 1994;272:1749–1756
  22. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale-preliminary report. Psychopharmacol Bull. 1973;9:13–28
  23. Lin EH, Von Korff M, Ludman EJ, et al. Enhancing adherence to prevent depression relapse in primary care. Gen Hosp Psychiatry. 2003;25(5):303–310
  24. Sullivan MD, Katon WJ, Russo JE, et al. Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. J Am Board Fam Pract. 2003;16(1):22–31
  25. Aikens JE, Nease DE, Klinkman MS, Schwenk T, Rodgers P. Personal models of depression account for antidepressant adherence rate. In: Proceedings of the 30th Annual Meeting of the North American Primary Care Research Group. 2002;
  26. Aikens JE, Nease DE, Klinkman MS, Pecora KE. What causes depressed patients to believe they need an antidepressant?. In: Proceedings of the 31st Annual Meeting of the North American Primary Care Research Group (NAPCRG). 2003;p. 19
  27. Karasz A, Sacajiu G, Garcia N. Conceptual models of psychological distress among low-income patients in an inner-city primary care clinic. J Gen Intern Med. 2003;18(6):475–477
  28. Brown C, Dunbar-Jacob J, Palenchar DR, Kelleher KJ, Bruehlman RD, Sereika S, et al. Primary care patients' personal illness models for depression: a preliminary investigation. Fam Pract. 2001;1:314–320

☆ Competing interests: James E. Aikens, PhD, is an employee of the University of Michigan and has served as an independent consultant to Pfizer, Inc. Kurt Kroenke, MD, has received research funding and honoraria as a consultant from Eli Lilly and Company, Pfizer, Inc., and Wyeth Pharmaceuticals. Ralph W. Swindle, PhD, is currently an employee of and stockholder in Eli Lilly and Company. Dr. Swindle has not received funding from any other source than Eli Lilly and Company over the last 5 years. Eli Lilly and Company funded the original ARTIST study, a randomized effectiveness trial of its SSRI antidepressant fluoxetine (Prozac), with paroxetine (Paxil) and sertraline (Zoloft). However, Eli Lilly and Company did not provide any funding for this manuscript.

☆☆ Author's contributions: JEA took primary responsibility for formulating the research questions, analyzing the data and writing all sections of the manuscript. KK and RWS each participated in the design and execution of ARTIST, assisted in interpreting the measures and results, and assisted JEA in writing the manuscript. GJE provided consultation to JEA on data analysis, managed the data and assisted in writing the manuscript. All authors read and approved the final manuscript.

PII: S0163-8343(05)00057-5

doi: 10.1016/j.genhosppsych.2005.04.001

General Hospital Psychiatry
Volume 27, Issue 4 , Pages 229-236 , July 2005

Article Tools

* Image Usage & Resolution